Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

详细信息    查看全文

• 作者：Irina Ghislain ; MS^a ; ^{irina.ghislain@eortc.be" class="auth_mail" title="E-mail the corresponding author} ; Efstathios Zikos ; MS^b ; Corneel Coens ; MS^a ; Chantal Quinten ; MS^b ; Vasiliki Balta ; MS^c ; Konstantinos Tryfonidis ; MD^a ; Prof Martine Piccart ; PhD^d ; Dimitrios Zardavas ; MD^e ; Eva Nagele ; PhD^f ; Prof Vesna Bjelic-Radisic ; PhD^f ; Fatima Cardoso ; MD^g ; Prof Mirjam A G Sprangers ; PhD^h ; Prof Galina Velikova ; PhDⁱ ; ^&dagger ; ; Andrew Bottomley ; PhD^a ; ^&dagger ; ; on behalf of the European Organisation for Research ; Treatment of Cancer (EORTC) Quality of Life Group
• 刊名：The Lancet Oncology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：17
• 期：7
• 页码：e294-e304
• 全文大小：306 K

文摘

Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies.